Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
Bottom Line: The present study evaluated the cost-effectiveness of eplerenone in the treatment of these patients in the UK and Spain.Probabilistic sensitivity analysis suggested a 100% likelihood of eplerenone being regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (UK) or €30 000 per QALY (Spain).By currently accepted standards of value for money, the addition of eplerenone to optimal medical therapy for patients with chronic systolic HF and mild symptoms is likely to be cost-effective.
Affiliation: BresMed, Sheffield, UK.Show MeSH
Related in: MedlinePlus
Mentions: A range of deterministic sensitivity analyses were carried out to test the robustness of the model projections by varying key inputs and assumptions. One-way parameter sensitivity analyses were performed by varying each parameter within its likely range using the 95% CIs of the parameter distributions (figure 2). In addition, a range of scenario analyses were conducted.